Analytical Data
-
Gene name
DEAF1
- Application
-
Alternative Names
Nuclear DEAF-1-related transcriptional regulator
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75398
-
Expression Region
1-565aa
-
Molecular Weight
65.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DEAF1 (Deformed Epidermal Autoregulatory Factor 1), a transcription factor belonging to the ZF (zinc finger) protein family, has garnered significant attention in recent years due to its crucial roles in various biological processes. Initially identified for its involvement in the regulation of epidermal development, DEAF1 has been linked to essential functions in cellular stress responses, immune modulation, and neuronal differentiation. Abnormal expression or dysfunction of DEAF1 has been implicated in several diseases, including cancer and neurodegenerative disorders, highlighting its potential as a therapeutic target. Researchers have increasingly turned to recombinant protein technologies to study DEAF1, allowing for the production of purified proteins for functional assays and structural analysis. These studies help elucidate DEAF1's role in gene regulation and its interaction with other molecular players in the cell. The use of DEAF1 recombinant protein in biochemical assays, such as DNA binding and transcriptional activation assays, has provided insights into its mechanisms of action. Moreover, understanding DEAF1's structural characteristics through techniques like X-ray crystallography or NMR can facilitate the development of small-molecule inhibitors or modulators that could have significant clinical implications. Overall, research on DEAF1 recombinant protein is essential for illuminating its biological functions and consequences of its dysregulation, paving the way for novel therapeutic approaches in related pathologies.
